Patent Granted for Fraudulent Science

The US Patent and Trademark Office has awarded patent protection to refuted discoveries on human stem cells.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, EKEMHwang Woo-Suk, whose debunked claims for having developed a stem cell line from cloned human embryos got him in serious trouble, has earned a US patent for the fraudulent research. Shoukhrat Mitalipov, a professor at Oregon Health and Science University, told The New York Times he was “shocked” by the news. “I thought somebody was kidding, but I guess they were not.”

According to The Korea Times, the US Patent and Trademark Office (USPTO) approved a patent for a stem cell line that was extracted from human embryos. RetractionWatch reported that this is the same stem cell line involved in two retracted Science papers, but that the patent did not make mention of that blemish in Hwang’s record. The patent is “definitely not an assertion by the U.S. government that everything he is claiming is accurate,” USPTO spokesman Patrick Ross told The New York Times.

Hwang's associate told The Korea Times that the patent will hopefully provide momentum for the infamous scientist’s work. “The USPTO acknowledged the technological edge of Hwang’s team,” said Hyun Sang-hwan at Chungbuk National ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies